06 Oct 2015 – BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance release first position paper identifying the key actions required to reinvigorate investment and R&D in the antibacterial field

The BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance, of which Destiny Pharma is a founding member, has released their first position paper entitled “Key Actions to Reinvigorate Investment and R&D in the antibacterial field Now” The paper urges European and National public authorities to take three key short term complementary actions with immediate effect:

1. Create a specific fund dedicated to small and medium biopharmas to finance projects from discovery to clinical proof of concept

2. Enhance market incentives to increase the attractiveness of developing new products tackling antimicrobial resistance

3. Strengthen the existing actions of the European Medicines Agency
(EMA) to accelerate and simplify the regulatory pathways for products
tackling antimicrobial resistance

The position paper also provides
some food for thought on longer-term perspectives to strengthen and
increase the R&D into new antibacterial drugs. Dr Bill Love, CEO of
Destiny Pharma said “The actions identified in the BEAM position paper
are intended to stimulate much needed investment into the development
of new antibacterial drugs. Europe needs to follow the USA, where positive
actions are being taken to incentivise companies to develop new drugs
to tackle the global public health crisis that multi-drug resistant
bacteria present.”

Leave a Reply

Your email address will not be published. Required fields are marked *